TLN-372 / Treeline Biosci - LARVOL DELTA

TLN-372-2501: A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advanced KRAS Mutant Solid Cancers (clinicaltrialsregister.eu) - P1/2 | N=20 | Not yet recruiting | Sponsor: Treeline Biosciences Inc.

New P1/2 trial • Oncology • Solid Tumor • KRAS

TLN-372-2501: A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advanced KRAS Mutant Solid Cancers (clinicaltrialsregister.eu) - P1/2 | N=20 | Recruiting | Sponsor: Treeline Biosciences Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • KRAS

A study of TLN-372 in Patients with Advanced KRAS Mutant Solid Tumors. (ANZCTR) - P1 | N=50 | Not yet recruiting | Sponsor: Treeline Biosciences, Inc.

New P1 trial • Oncology • Solid Tumor • KRAS

Treeline Announces First Clinical Trials and Secures $200M in Additional Funding (Businesswire) - "Treeline Biosciences (or Treeline) today announced the initiation of Phase 1 trials for two internally discovered programs, TLN-121 and TLN-372, and a third in-licensed program, TLN-254."

Financing • Trial status • Lymphoma • Solid Tumor

TLN-372 in Advanced KRAS Mutant Solid Tumors (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Treeline Biosciences, Inc.

New P1 trial • Oncology • Solid Tumor • KRAS